You can buy or sell SYN and other stocks, options, ETFs, and crypto commission-free!
Synthetic Biologics, Inc., also called Synthetic Biologics, is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. Read More The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
52 Week High
52 Week Low
Seeking AlphaFeb 27
Synthetic Biologics Inc. (SYN) CEO Steven Shallcross on Q4 2018 Results - Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:14 PM ET Synthetic Biologics Inc. (NYSEMKT:SYN) Q4 2018 Earnings Conference Call February 27, 2019 16:30 ET Company Participants Vincent Perrone - Director, Corporate Communications Steven Shallcross - CEO & CFO Vince Wacher - Head, Product & Corporate Development Conference Call Participants Katherine Xu - William Blair Jim Molloy - Alliance Global Partners Operator Good afternoon and welcome to the Synthetic Biologics 2018 Year End Investor Conference Call. ...
PR NewswireFeb 27
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results
ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a clinical-stage company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a clinical programs update and reported financial results for the year ended December 31, 2018. "During the fourth quarter, we remained sharply focused on executing our strategy to advance and demonstrate the significant value of our portfolio of GI and microbiome-focused clin...
Expected May 7, After Hours